Effect and safety of sorafenib in patients with intermediate hepatocellular carcinoma who received transarterial chemoembolization: A retrospective comparative study

Table 2 Univariate analysis of all patients for overall survival

Characteristic	n (%)	mOS (mo)	95%CI	P value	χ2
Gender
Male	42 (62.7)	33.4	28.03-38.77	0.659	0.195
Female	25 (37.3)	35.2	30.40-40.00
Age (yr)
≥ 57	26 (38.8)	33.0	29.34-36.66	0.178	1.818
< 57	41 (61.2)	35.2	32.58-37.82
Child-Pugh
A	44 (65.7)	35.2	31.00-39.40	0.000	17.805
B	23 (34.3)	21.0	16.22-25.78
Tumor diameter (cm)
≥ 6	24 (35.8)	20.0	14.51-25.49	0.016	5.815
< 6	43 (64.2)	35.2	32.63-37.77
Serum albumin (g/L)
≥ 35	36 (53.7)	36.0	33.34-38.66	0.066	3.39
< 35	31 (46.3)	23.0	18.25-27.75
Serum bilirubin (umol/L)
≥ 20	19 (28.4)	24.0	18.27-29.73	0.006	7.612
< 20	48 (71.6)	35.0	32.52-37.48
LDH (U/L)
≥ 245	39 (58.2)	28.0	24.83-31.17	0.143	2.143
< 245	28 (41.8)	33.0	31.19-34.81
AFP (ng/mL)
≥ 200	44 (65.7)	28.0	20.50-35.50	0.011	6.448
< 200	23 (34.3)	32.0	25.86-38.14
Number of TACE
≥ 2	33 (49.3)	29.8	23.14-36.46	0.079	3.809
< 2	34 (50.7)	36.6	35.12-38.08
Sorafenib + TACE	38 (56.7)	35.2	30.02-40.38	0.000	12.645
TACE	29 (43.3)	22.0	21.23-22.77

OS: Overall survival; LDH: Lactatedehydrogenase; AFP: α-fetoprotein; TACE: Transarterial chemoembolization; CI: Confidence interval.